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1Department of Ophthalmology, Children’s Hospital Boston, Boston, MA; 2Department of Ophthalmology, Harvard Medical School,
Boston, MA
Purpose: Longitudinal studies in rat models of retinopathy of prematurity (ROP) have demonstrated that abnormalities
of retinal vasculature and function change hand-in-hand. In the developing retina, vascular and neural structures are under
cooperative molecular control. In this study of rats with oxygen-induced retinopathy (OIR) models of ROP, mRNA
expression of vascular endothelial growth factor (VEGF), semaphorin (Sema), and their neuropilin receptor (NRP) were
examined during the course of retinopathy to evaluate their roles in the observed neurovascular congruency.
Methods: Oxygen exposures designed to induce retinopathy were delivered to Sprague-Dawley rat pups (n=36) from
postnatal day (P) 0 to P14 or from P7 to P14. Room-air-reared controls (n=18) were also studied. Sensitivities of the rod
photoreceptors (Srod) and the postreceptor cells (Sm) were derived from electroretinographic (ERG) records. Arteriolar
tortuosity, TA, was derived from digital fundus images using Retinal Image multi-Scale Analysis (RISA) image analysis
software. mRNA expression of VEGF164, semaphorin IIIA (Sema3A), and neuropilin-1 (NRP-1) was evaluated by RT–
PCR of retinal extracts. Tests were performed at P15–P16, P18–P19, and P25–P26. Relations among ERG, RISA, and
PCR parameters were evaluated using linear regression on log transformed data.
Results: Sm was low and TA was high at young ages, then both resolved by P25–P26. VEGF164 and Sema3A mRNA
expression were also elevated early and decreased with age. Low Sm was significantly associated with high VEGF164 and
Sema3A expression. Low Srod was also significantly associated with high VEGF164. Srod and Sm were both correlated with
TA. NRP-1 expression was little affected by OIR.
Conclusions: The postreceptor retina appears to mediate the vascular abnormalities that characterize OIR. Because of the
relationships revealed by these data, early treatment that targets the neural retina may mitigate the effects of ROP.
High oxygen has long been associated with pathologic
retinal vascular abnormalities [1–4], the clinical hallmark of
retinopathy  of  prematurity  (ROP)  [5].  But  persistent
dysfunction of the neural retina is increasingly recognized as
an essential component of the ROP disease process. Persistent
deficits in rod and rod-bipolar cell sensitivity are detectable
years after acute ROP has resolved [6–11]. The severity of
these neural deficits varies with the degree of the antecedent
vascular disease. The abnormalities in retinal blood vessels
that characterize ROP appear within a narrow preterm age
range when the developing rod outer segments are elongating
rapidly, accompanied by an increase in the rhodopsin content
of  the  retina  and  burgeoning  energy  demands  in  the
photoreceptors [12].
In rat models of ROP, rod photoreceptor dysfunction
antedates  [13]  and  predicts  [14]  the  subsequent  retinal
vascular abnormalities, and persists after their resolution [14,
15]. The mechanisms that underpin these phenomena remain
to be elucidated.
The  postreceptor  retina,  too,  is  affected  by  ROP.
Moreover,  postreceptor  sensitivity  recovers  hand-in-hand
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with resolution of the retinal vascular abnormalities [14,15].
Indeed, the retinal vasculature and the postreceptor neural
retina are in close physical proximity, are immature at the
same  ages,  and  develop  together  by  processes  termed
angiogenesis  and  neurogenesis,  respectively.  It  stands  to
reason that there must be “remodeling” [16] mechanisms that
mediate  the  neurovascular  congruency.  Molecules,  called
growth factors, that cooperatively control both angiogenesis
and neurogenesis [17] are abundant in the developing retina,
and,  thus,  are  candidate  mediators  of  the  neurovascular
interplay documented in ROP. We studied mRNA expression
of neurovascular growth factors in rat models of ROP.
From the angiogenesis pathway, we selected vascular
endothelial  growth  factor  (VEGF).  VEGF  is  essential  for
normal blood vessel growth in the developing retina [18,19]
and  is  implicated  in  the  pathogenesis  of  vasoproliferative
retinal diseases like ROP [20–22]. From the neurogenesis
pathway, we selected semaphorin because it acts as an axon
growth cone guidance molecule [23] involved in postreceptor
retinal development and likely in plasticity and stabilization
(as during recovery from an insult) of postreceptor signaling
[24]. We also assayed neuropilin-1 (NRP-1), a coreceptor for
both  VEGF  [25,26]  and  semaphorin  [27,28].  NRP-1  is
expressed both in vascular endothelial cells and in retinal
neurons [29], including in the progenitors of photoreceptors
[30].  That  NRP-1  mediates  both  neural  and  vascular
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2499development  by  the  competitive  binding  of  two  disparate
ligand  families,  VEGF  and  semaphorin,  supports  the
hypothesis  that  retinal  neurogenesis  and  angiogenesis  are
inseparably linked [31,32]. This is further supported by the
observation that VEGF, semaphorin, and NRP-1 are expressed
in  temporally  and  spatially  overlapping  domains  during
retinal development [24,33]. In addition, semaphorins play a
direct role in angiogenesis not mediated by neuropilin [34–
36]. Thus, as has been documented in oncogenesis where
semaphorins have a demonstrated role in the development of
vascular supply [37], semaphorins likely play a role in the
development of retinal vasculature as well as retinal neurons.
We selected specific isoforms of VEGF and semaphorin
based upon the degree of specificity in VEGF/neuropilin and
semaphorin/neuropilin binding affinity and activity. NRP-1 is
specifically sensitive to the VEGF164 isoform (VEGF164) [26],
the  ortholog  of  primate  VEGF165,  and  of  the  semaphorin
family of ligands, has highest affinity for semaphorin IIIA
(Sema3A) [38]. Herein, we studied the mRNA expression of
these growth factors in rats with oxygen-induced retinopathies
(OIR) that model the gamut of severity of human ROP [14].
In every rat, we also obtained numeric measurements of rod
photoreceptor and postreceptor neural function and of blood
vessel abnormality.
METHODS
Subjects: This study followed a cross-sectional design and
used  54  Sprague-Dawley  albino  rats  (Charles  River
Laboratories Inc., Worcester, MA) from nine litters. Rats were
assigned to one of three groups (n=18), either of two OIR
paradigms  or  controls.  Tests  of  neural  function,  vascular
abnormality,  and  growth  factor  mRNA  expression  were
performed at postnatal day (P) 15–P16, P18–P19, or P25–P26.
P15–P16 is immediately after the induction of ROP. At P18–
P19, the vascular abnormalities are quite marked [14,15]. At
P25–P26, vascular abnormalities are rapidly resolving [14,
15]. All experiments were conducted according to the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research  with  the  approval  of  the  Animal  Care  and  Use
Committee at Children’s Hospital Boston.
Induction of retinopathy: As described previously in detail
[14],  OIR  was  induced  by  placing  pups  and  dam  in  an
OxyCycler (Biospherix Ltd., Lacona, NY) and exposing them
to one of two different oxygen regimens designed to produce
a range of effects on the retinal vasculature and the neural
retina.  The  first  OIR  regimen,  the  50/10  model,  involved
exposure to alternating 24 h periods of 50±1% and 10±1%
oxygen from P0 (the day of birth) to P14 [39]. The second
OIR regimen, the 75 model, was exposure to 75±1% oxygen
from  P7  to  P14.  Controls  were  reared  in  room  air  (21%
oxygen). While the 50/10 model reliably produces peripheral
neovascularization [39] and tortuosity of the posterior retinal
arterioles  [14,15],  rat  models  created  by  exposure  to
continuous high oxygen, similar to our 75% model, reliably
produce tortuosity of the central retinal vasculature [14], but
infrequently produce peripheral neovascularization [40,41].
Both OIR paradigms target the ages at which the rod outer
segments are forming and when the rhodopsin content of the
retina is rapidly increasing. Of note, at birth, about 50% of the
eventual rod photoreceptors are differentiated; however, only
a small number of the second-order bipolar cells are present.
By  P9,  differentiation  of  both  rod  photoreceptor  and
postreceptor neurons is essentially complete [42]. But rod
outer segment development and vascular coverage remain
incomplete.
Analyses of neural function:
Calibration of stimuli—Function of rod photoreceptor
and  postreceptor  retinal  neurons  was  assessed  by
electroretinography (ERG). The stimuli were delivered using
an Espion e2 with ColorDome Ganzfeld stimulator (Diagnosys
LLC, Lowell, MA). The rate of photoisomerization per rod
(R*) for the green LED flash was calculated by measuring the
flux density incident upon an integrating radiometer (IL1700;
International  Light,  Newburyport,  MA)  positioned  at  the
location of the rats’ cornea, and following the procedures
detailed by Lyubarsky and Pugh [43]. The LED was treated
as monochromatic with λ equal to 530 nm. The intensity of
the flash was given by
i(λ) = Q(λ) × T(λ) ×
apupil
aretina
× arod(λ)
Equation
where i(λ) is the number of photoisomerizations per rod (R*)
elicited by the flash, Q(λ) is the calculated photon density at
the cornea, T(λ) is the transmissivity of the ocular-media and
pre-receptor retina (approximately 80% at 530 nm [44]), and
apupil,aretina, and arod(λ) are respective estimates of the area of
the dilated pupil (approximately 20 mm2 [45]), the area of the
retinal surface (approximately 50 mm2 [46]), and the end-on
light collecting area of the rod photoreceptor (approximately
1.5 µm2 at 530 nm). arod(λ) takes into account the length of the
outer segment, the absorption spectrum of the rod, and the
optical density of the photopigment, as well as the radius of
the  photoreceptor  [47].  Since  several  of  these  parameter
values are unknown for the rat rod that is affected by OIR,
stimuli are expressed as the expected values in adult control
rats. We calculated Q(λ) by
Q(λ) = λ ×
Pλ
h × c
Equation
where Pλ is the radiant flux (watts), h is Planck’s constant, and
c   is   the   speed   of   light  [48].  To  evaluate  the  intensity  of
“white” xenon  arc flashes,  we  recorded  an  intensity series
with interspersed green and white flashes and  estimated  the
1
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2500equivalent light based on the shift of the stimulus/response
curves for the scotopic b-wave.
Preparation—Prior  to  ERG  testing,  rats  were  dark
adapted for a minimum of 2.5 h. Preparations were made
under dim red illumination. Subjects were anesthetized with
a loading dose of approximately 75 mg·kg−1 ketamine and
approximately  7.5  mg·kg−1  xylazine,  injected
intraperitoneally. This was followed, if needed, by a booster
dose (50% of loading dose) administered intramuscularly. The
pupils were dilated with a combination of 1% phenylephrine
hydrochloride  and  0.2%  cyclopentolate  hydrochloride
(Cyclomydril; Alcon, Fort Worth, TX). The corneas were
anesthetized  with  one  drop  of  0.5%  proparacaine
hydrochloride  (Alcon).  A  Burian-Allen  bipolar  electrode
(Hansen  Laboratories,  Coralville,  IA)  was  placed  on  the
cornea and the ground electrode was placed on the tail.
Analysis of rod function—Sample ERG responses are
shown in Figure 1A. The a-wave results from the suppression
of the circulating current of the photoreceptors.
Rod function was evaluated by ensemble fitting the Hood
and Birch formulation [49] of the Lamb and Pugh model [50,
51] of the activation of phototransduction to the leading edge
of ERG a-waves elicited by five bright white flashes (Figure
1B). The model takes flash intensity, i (R*) and elapsed time,
t (sec), as its inputs, such that
P3(i, t) = (1 − exp ( −
1
2 × Srod × i × (t − td)2)) × RmP3
for t  < t < 20 ms d Equation
where Srod is the sensitivity measure (R*−1·sec−2), td is a delay
of approximately 3.5 ms, and RmP3 is the saturated amplitude
of the photoreceptor response (μV). Fitting was restricted to
the a-wave trough. Srod summarizes the amplification time
constants involved in the activation of phototransduction.
Analysis of postreceptor function—The amplitude of
the b-wave was measured from the trough of the a-wave to the
peak. At low intensities, under dark adapted conditions, the b-
wave  reflects  mainly  the  activity  of  the  rod  bipolar  cells
(Figure 1C) [52,53]. Sensitivity of the b-wave is defined in
the linear range of the response/intensity relationship as the
amplitude of the b-wave scaled by stimulus intensity [54]. The
b-wave amplitude increases in linear proportion to stimulus
intensity over a narrow range of dim flash intensities [55].
Therefore, we calculated the sensitivity at threshold by scaling
the amplitude of each b-wave by the intensity used to elicit it
and fitting:
Sf (i)
Sm =
i −1
i −1 + i12
Equation
3
4
Figure  1.  Electroretinographic  (ERG)
analyses  of  rod  photoreceptor  and
postreceptor         neural          function. 
A:   Sample   (ERG)  responses    from
a   P25–P26   control   rat   elicited  with
green LED (left) and “white” xenon arc
(right) full field stimuli. The number of
rhodopsin photoisomerizations per rod
(R*) produced by each flash is indicated
at  the  end  of  each  trace.  Traces  are
numbered for reference in panels B and
C.  B:  Determination  of  rod
photoreceptor  function.  Sensitivity  of
the rods, Srod, is determined by fit of
Equation 3 (red dashes) to the leading
edge of ERG a-waves (circles) elicited
with bright flashes. For this subject, Srod
was 3.79 R*−1·s−2. C: Determination of
postreceptor  function.  The  b-waves
elicited by dim flashes (left panel) were
scaled by the intensity of the flash used
to  elicit  them  (middle  panel)  and  the
Michaelis–Menten  equation  with  the
exponent set to −1 (Equation 4) fit to the
resulting  scaled  response  amplitudes
(right panel). The limit of the function
as  intensity  approaches  zero,  Sm,
defines postreceptor sensitivity. For this
subject, Sm was 224 µV·R*−1.
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2501to the resulting sensitivities. Sf (µV·R*−1) is the fractional
sensitivity of the b-wave response to a flash of i intensity, Sm
(µV·R*−1)  is  the  sensitivity  of  the  postreceptor  retina  at
threshold,  and  i1/2  (R*)  is  the  stimulus  intensity  at  which
sensitivity has fallen to half that at threshold.
Analysis of retinal vessels: In the same experimental sessions,
digital photographs of the fundi of both eyes were obtained
(RetCam; Clarity Medical Systems Inc., Dublin, CA). Several
images were assembled into a composite (Photoshop CS3;
Adobe Systems Inc., San Jose, CA) to create a complete view
of the posterior pole, defined as the region within the circle
bounded by the vortex veins and concentric to the optic nerve
head  (ONH).  The  arterioles  were  identified  and  their
tortuosity measured using Retinal Image multi-Scale Analysis
(RISA) software as previously described in detail [14]. In
summary, arterioles were cropped from the main image and
segmented individually. The segmented image was manually
edited to remove extraneous features such as the background
choroidal vasculature. RISA constructed a vessel skeleton
from  which  the  integrated  curvature  of  the  arteriole  was
measured. Integrated curvature, the sum of angles along a
vessel  normalized  by  its  length,  has  demonstrated  good
agreement  with  human  observer  assessments  of  arteriolar
tortuosity [56]. Arteriolar tortuosity, TA (radians·pixel−1), was
calculated for each subject as the mean integrated curvature
of all measurable arterioles in both eyes (median 9).
Analysis of growth factor expression:
Tissue  preparation—Rats  were  euthanized  with
approximately  100  mg·kg−1  pentobarbital  administered
intraperitoneally. Their corneas were incised and both retinas
extracted. These were pooled, flash frozen in liquid nitrogen,
and stored at −80° C.
RT–PCR—RNA was extracted using an RNeasy Mini
Kit (Qiagen, Valencia, CA). The quantity of RNA extracted
was  determined  spectrophotometrically  (SmartSpec  3000;
Bio-Rad Laboratories Inc., Hercules, CA). cDNA was reverse
transcribed from each RNA sample in triplicate to mitigate the
effects of noise and error. In each of three sample tubes, a
quantity of RNA solution containing 300 ng of RNA was
added to a solution of 8 µl 5X iScript Reaction Mix and 2 µl
iScript Reverse Transcriptase (iScript cDNA Synthesis Kit;
Bio-Rad). Nuclease-free water was then added to obtain a
final volume of 40 µl per sample. Reverse transcription was
achieved by incubating the mixtures at 25 °C for 5 min, 42 °C
for 30 min, and 85 °C for 5 min. cDNA was stored at −20 °C.
PCR  was  performed  on  all  three  cDNA  products
employing  primers  (Table  1)  for  VEGF164,  NRP-1,  and
Sema3A and using an appropriate temperature gradient. In
addition,  glyceraldehyde  3-phosphate  dehydrogenase
(GAPDH) served as the internal control.
Each reaction contained 3.0 µl cDNA and the following
reagents (Bio-Rad): 5.0 µl 10x iTaq buffer, 1.5 µl 50 mM
MgCl2,  1.0  µl  10  mM  dNTP  mix,  0.25  µl  iTaq  DNA
polymerase, 15 µl 10 mM forward primer, 15 µl 10 mM
reverse primer, and 9.25 µl sterile water for a total volume of
50  µl  per  reaction.  The  linear  range  of  each  target  was
determined empirically by increasing the number of cycles
and resolving the products on a 2% agarose gel (Bio-Rad).
The  12  products  of  RT–PCR  (three  each  for  VEGF164,
NRP-1, Sema3A, and GADPH) and a molecular ruler (EZ-
Load 100 bp; Bio-Rad) were resolved on a single 2% agarose
gel. Gel imaging was performed using a GEL Logic 100
imaging system with Stratagene Transilluminator 2040 EV
(Kodak Scientific Imaging Systems, New Haven, CT). The
optical density of each band was determined (ImageJ version
1.38x;  NIH,  Bethesda,  MD).  The  optical  density  of  each
growth factor band was divided by the optical density of its
corresponding control gene (GAPDH) band. The two ratios in
closest agreement for each growth factor were averaged in
subsequent analyses.
Selection  of  control  gene—Though  commonly
employed  as  an  internal  standard  in  experimental  OIR,
GAPDH expression is reportedly altered in severe hypoxia
[57]. To assure the suitability of GAPDH as a control gene in
the OIR models, we ran a pilot study on three 50/10 model,
three 75 model, and three control rats (aged P15–16). β-Actin
mRNA and 18S rRNA expression, as well as GAPDH, were
measured  in  this  study.  The  ratio  of  the  former  genes
expression to GAPDH was taken. The expression ratios were
nearly  constant  across  group  (<0.1  log  unit  maximum
difference). Specifically, in 75 model rats the expression of
β-Actin  and  18S  were  each  approximately  +0.01  log  unit
relative to controls; between 50/10 model and control rats, the
change  was  approximately  +0.1  log  unit  for  β-Actin  and
−0.1  log  unit  for  18S.  Thus,  GAPDH  appears  to  be  an
appropriate control gene in our experiment.
Data analyses: All data were expressed as ΔLogNormal for
the P25–26 controls:
TABLE 1. PCR PRIMERS
Target Primer sequence (5′-3′)
Annealing
temp
(°C)
Product
length
(bp)
VEGF164 F: AACCATGAACTTTCTGCTCTC 52.8 635
  R: TTGTCACATCTGCAAGTACG 52.8
NRP-1 F: GAAGGAGGGAAATAAAGCCA 52.3 572
  R: CTGATGAATCTTGTGGAGAG 50.2
Sema3A F: GACAACTTTCCTGAAAGCAC 51.9 535
  R: CCACTTTAAGGACAGTTCCA 52.1
GAPDH F: CATGTTCCAGTATGACTCTACC 52.3 829
  R: GTTGCTGTAGCCATATTCATTGTC 54.3
The table provides key details of the primers used in the RT–
PCR  experiments. The growth factors studied were vascular
endothelial growth factor 164 (VEGF164), semaphorin IIIA
(Sema3A),  and  neuropilin-1  (NRP-1 );  glyceraldehyde  3-
phosphate dehydrogenase (GAPDH ) served as the internal
control. The length of the product of the reaction is given in
base pairs (bp).
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2502ΔLogNormal(x) = log(x) −
∑
rat=1
n
log (P25-26CTLrat)
n
By expressing the data in log values, changes in observations
of fixed proportion, either up or down, become linear. This is
consistent  with  a  constant  fraction  for  physiologically
meaningful changes in parameter values. Normalization by
the  mean  of  controls  at  P25–P26  allowed  evaluation  of
changes with age. All parameters (Srod, Sm, TA, and mRNA
expression of VEGF164, NRP-1, and Sema3A) were evaluated
by ANOVA with factors age (P15–P16, P18–P19, P25–P26)
and group (50/10 model, 75 model, control). Posthoc testing
was performed using Tukey’s honestly significant difference
(q)  statistical  test.  Relations  between  parameters  were
evaluated  by  Pearson  product  moment  correlation.  The
significance level (α) for all tests was p<0.01.
RESULTS
Figure 2 shows representative fundus images and the retinal
arterioles as segmented by RISA from a 50/10 model, a 75
model,  and  a  control  rat  imaged  at  P25–26.  The  average
tortuosity of the arterioles, TA (radians∙pixel), was highest in
the 75 model rat and lowest in the control.
Figure  3  plots  mean±SEM  ΔLogNormal  rod
photoreceptor sensitivity, Srod, postreceptor sensitivity, Sm,
and arteriolar tortuosity, TA. Srod was not significantly affected
by OIR or age. However, Sm was significantly affected by
OIR (F=32.2; df=2,45; p<0.001), being more than 0.6 log unit
below control values in both OIR models at early ages (P15–
P16,  P18–P19),  but  recovered  significantly  by  P25–P26
(F=19.5; df=2,45; p<0.001). The results for TA mirrored those
for Sm, with TA high when Sm was low and TA becoming lower
when Sm increased. TA was high in OIR rats (F=73.4; df=2,45;
p<0.001) at early ages but became significantly more normal
by  P25–P26  (F=29.0;  df=2,45;  p<0.001).  Of  note,  Sm
remained markedly low even at P25–P26 in 50/10 model rats,
while TA remained markedly high in 75 model rats. Figure 4
plots the three interrelations between these parameters (Srod
versus Sm, Srod versus TA, and Sm versus TA) across age and
group.  All  three  parameters  were  correlated.  Postreceptor
sensitivity depends in part upon photoreceptor sensitivity, and
these  parameters  (Srod,  Sm)  were  positively  correlated.
Consistent  with  previous  findings  in  OIR  rats,  high  TA
correlated with low Srod. However, the value of the correlation
coefficient was larger between Sm and TA than between Srod
and TA. Indeed, 33 of the 36 OIR rats tested had reduced
postreceptor sensitivity and increased vascular abnormalities
relative to the mean for P25–P26 controls, and 29 fell outside
the range of values observed in the controls at any age.
Figure 5 plots mean±SEM ΔLogNormal growth factor
mRNA  expression  for  VEGF164,  NRP-1,  and  Sema3A.
Expression  of  the  ligands  VEGF164  and  Sema3A  was
Figure 3. Mean±SEM ΔLogNormal (Equation 5) ERG and blood
vessel parameters for 50/10 model, 75 model, and control rats at P15–
P16, P18–P19, and P25–P26. Note that mean ΔLogNormal for P25–
P26 control rats is zero. A: Sensitivity of the rod photoreceptors,
Srod, and postreceptor neural retina, Sm. B: Arteriolar tortuosity, TA.
Figure  2.  Composite  RetCam  images
(top panels) and the retinal arterioles as
segmented  by  RISA  (bottom  panels).
The images were obtained from a 50/10
model, a 75 model, and a control rat at
P25–26. The posterior pole, defined as
the region bounded by the vortex veins
and concentric to the optic nerve head,
is  indicated  (circles).  The  integrated
curvatures  (radians∙pixel−1)
corresponding to each segmented vessel
are given. The mean tortuosity of the
arterioles, TA (radians∙pixel−1), for each
eye is given at the bottom of the figure.
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2503Figure 4. Relations of neural and vascular parameters for 50/10
model (red), 75 model (green), and control (blue) rats. Symbols
indicate age at test (key). Postreceptor sensitivity, Sm, is plotted as a
function of rod photoreceptor sensitivity, Srod (top panel). Arteriolar
tortuosity (TA) is plotted as a function of Srod (middle panel) and Sm
(bottom panel). The left ordinates and bottom abscissae are expressed
in derived (Equation 5) ΔLogNormal units; the right ordinates and
top abscissae are linear values. Stippled lines indicate the means for
the P25–P26 controls. Solid lines are orthogonal linear regressions
through all the data. Low Srod was significantly related to low Sm
(r=0.35; p=0.009) and high TA (r=-0.40; p=0.003). Low Sm was also
significantly related to high TA (r=-0.62; p<0.001).
significantly  altered  in  OIR  rats.  In  both  OIR  models,
VEGF164, mainly associated with angiogenesis, was elevated
at early ages (P15–P16, P18–P19) and decreased significantly
with  age  (F=7.5;  df=2,45;  p=0.002)  to  levels  well  below
normal at P25–P26. In control rats, VEGF164 changed little
with age. Sema3A, mainly associated with neurogenesis, was
significantly elevated in 50/10 model rats (F=8.4; df=2,45;
p=0.001);  75  model  rats  did  not  significantly  differ  from
controls. NRP-1, a receptor for both VEGF164 and Sema3A,
displayed no significant effect of group or age (nor a group by
age interaction).
As shown in Figure 6, across group and age, deficits in
postreceptor sensitivity (Sm) were negatively correlated with
VEGF164  and  Sema3A  mRNA  expression.  NRP-1  receptor
mRNA was weakly negatively associated with postreceptor
sensitivity (p=0.011, not shown). Overexpression of VEGF164
is documented in OIR models and is also known to promote
pathological  angiogenesis  [58,59].  High  expression  of
VEGF164 mRNA was a significant predictor of high TA. Srod
was, in turn, negatively correlated with VEGF164 expression;
that is, poor rod function was associated with high VEGF164
mRNA.
DISCUSSION
In these rats with OIR, the function of the postreceptor neural
retina was significantly altered. Postreceptor sensitivity, Sm,
was low in both OIR models at P15–P16 but recovered with
age (Figure 3). These age-related improvements in neural
function were accompanied by improvements in the vascular
parameter, TA. In addition, we found that Sm, which measures
postreceptor sensitivity at threshold, was correlated with TA
in these OIR rats (Figure 4). Rod photoreceptor sensitivity,
Srod, was also correlated with TA, though the strength of the
correlation was weaker. The mRNA expression of growth
factors  mediating  both  angiogenesis  and  neurogenesis,
expressed relative to normal, was also altered (Figure 5). We
found that mRNA of VEGF164 was elevated in OIR rats, in
agreement with other reports [58,59]. To our knowledge, this
is the first report of alterations in a “neural” growth factor in
OIR; Sema3A mRNA expression was upregulated in 50/10
model rats.
Figure 5. Mean±SEM ΔLogNormal (Equation 5) mRNA expression.
Growth factor expression data for the 50/10 model, 75 model, and
control rats at P15–16, P18–19, and P25–26 are shown. Note that
mean ΔLogNormal for P25–26 control rats is zero.
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depends  upon  the  extent  of  earlier  rod  photoreceptor
dysfunction, although the rods and the retinal blood vessels
are anatomically separated. We replicated the finding [14] that
low  rod  sensitivity  (Srod)  predicts  abnormal  blood  vessels
(TA; Figure 4). Srod was, in turn, negatively correlated with
VEGF164 expression (Figure 6). The postreceptor neural retina
is driven by rod photoreceptors in the outer retina, and is
supplied by the retinal vasculature that traverses the inner
retinal surface, sending capillaries deep into the inner neural
layers. Thus, the postreceptor neural retina may be the bridge
between rods and retinal vasculature and is in a position to
mediate  the  rod  and  retinal  vascular  relation  (Figure  4).
Consistent  with  this  position,  in  these  data,  postreceptor
sensitivity  was  significantly  associated  not  just  with  rod
function and vascular abnormality (Figure 4), but also with
mRNA expression of VEGF164 and Sema3A (Figure 6).
There are at least two explanations for the strong negative
relation between Sm and TA: 1) the pathologic vasculature
associated  with  high  values  for  TA  presumably  adversely
Figure  6.  Significant  relations  between  growth  factor  mRNA
expression,  photoreceptor  and  post-receptor  sensitivity,  and
arteriolar tortuosity. Results from RT–PCR (VEGF164, Sema3A),
ERG (Srod, Sm), and RISA (TA) analyses for 50/10 model (red), 75
model (green), and control (blue) rats are plotted with different
symbols indicating age at test (key). The left ordinates and bottom
abscissae are expressed in derived (Equation 5) ΔLogNormal units;
the right ordinates and top abscissae are linear values. Stippled lines
indicate  the  means  for  the  P25-P26  controls.  Solid  lines  are
orthogonal linear regressions through all the data. Low Sm was
significantly associated with high VEGF164 (r=-0.49; p<0.001) and
Sema3A  expression  (r=-0.38;  p=0.005).  Elevated  VEGF164  was
related to high TA (r=0.35; p=0.009). Low Srod was significantly
related to high VEGF164 (r=-0.39; p=0.003).
affects  the  retinal  circulation,  while  low  values  for  TA
putatively represent a salubrious postreceptor environment
favorable to Sm; 2) the distressed postreceptor neural retina
may signal the need for improved circulation by upregulating
mRNA of proangiogenic growth factors such as VEGF or
semaphorins.  An  excess  of  these  signals  may  induce  the
pathologic  vasculature  that  resulted  in  high  TA.  These
explanations  are  not  necessarily  mutually  exclusive.
However, although Sema3A expression was markedly altered
by OIR, it was not a significant predictor of blood vessel
tortuosity.
Since  rod  photoreceptor  dysfunction  antedates  and
predicts  consequent  vascular  abnormality  [14],  rod
dysfunction  may  underpin  both  postreceptor  neural
dysfunction  and  retinal  vascular  abnormality.  Deficits  in
postreceptor sensitivity in OIR are presumably due, in part, to
diminished rod signaling, but may be worsened by direct
insult to the rod bipolar cell, such as from hypoxia consequent
to an avascularized inner retina and exacerbated by oxygen-
demanding  neighboring  rods.  Natural  responses  in  the
postreceptor retina would be to: 1) remodel neuron-to-neuron
connections to enhance sensitivity; and 2) promote vascular
development. Both outcomes could be achieved through the
mediation of growth factors such as VEGFs and semaphorins
expressed by intermingled glia [60,61].
Two retinal targets for intervention are suggested by these
data, the molecular crosstalk between postreceptor neurons
and their vasculature and the immature rod photoreceptors
themselves. Mitigation of VEGF, either by the reduction of its
expression or by antagonism of its receptors, has garnered
much attention [62–66]. Successful treatment of the retinal
vasculature would result in enhanced vascular supply to the
postreceptor  neurons  and  presumably  improve  visual
function.  However,  in  our  data,  at  early  ages  when
postreceptor  sensitivity  was  low,  VEGF  expression  was
elevated.  As  postreceptor  sensitivity  recovered,  VEGF
expression plummeted. Endogenous VEGF is required for
visual  function  [67].  Possibly,  the  high  VEGF  expression
instigated successful receptor remodeling. Indeed, anti-VEFG
pharmaceuticals  have  the  potential  for  adverse  effects  on
developing neurons [67–69], and thus any anti-VEGF therapy
in ROP calls for caution. Moreover, since neural dysfunction
antedates the vascular abnormalities [13], it seems unlikely
that  anti-VEGF  therapy  alone  can  fully  normalize  retinal
function in ROP.
If the rods mediate the neurosensory dysfunction in ROP,
then treatments that protect the rods may also protect the
postreceptor  neurons  and  would  possibly  reduce  VEGF
expression.  Thus,  treatments  designed  to  relieve  the
burgeoning aerobic demands of the immature rods during the
ages when the rod outer segments are elongating should be
among  the  treatments  considered  for  ROP.  Simple
approaches,  such  as  treatment  with  light  to  suppress  the
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2505circulating current [70], have shown small beneficial effect in
OIR rats [71]. Pharmaceutical protection of the immature rods
therefore represents a promising, though untested, approach
to the management of ROP [72].
It should be noted that several recent approaches may
derive some of their efficacy from neuroprotective effects. For
example, omega-3 polyunsaturated fatty acids (ω3-PUFAs)
increased vessel regrowth after the induction of retinopathy
in a mouse model of ROP, reducing consequent pathologic
vascularization [73]. One action of ω3-PUFAs is to lower
inflammatory cytokine production in retinal microglia in the
inner retina, directly mediating angiogenesis. However, ω3-
PUFAs  are  also  neuroprotective  during  ischemia  [74],
suggesting that some of their effect on the retinal vasculature
may,  in  fact,  be  due  to  preservation  of  rod  function.
Unfortunately, we are unaware of any assessments of retinal
function that have been applied, to date, in an antiangiogenic
treatment in OIR models, leaving the role of the rods and
postreceptor neurons equivocal.
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